After Pfizer And GSK, India’s Agila Teams Up With Lilly For Oncology Drugs In Emerging Markets
This article was originally published in PharmAsia News
Executive Summary
Over the last year, Agila has gone ballistic with its filings and approvals for anti-cancer injectables in the U.S., and after inking a deal with Lilly, it is likely to reach a new high.